Myriad, Sanofi to team on diabetes biomarker Dx discovery work

A Myriad Genetics ($MYGN) subsidiary will team up with Sanofi ($SNY) and others to conduct protein biomarker discovery work on more than 8,000 serum samples from prediabetes or Type 2 diabetes patients. The goal of the project: Identify biomarkers that could help improve patient care and treatment. Myriad said the deal could generate up to $10 million in companion diagnostic service revenue over the next two fiscal years. Myriad may need the extra revenue as it revs up for a U.S. Supreme Court fight over whether it has the right to own intellectual property for isolated genes involved in its cancer diagnostics. Release

Sponsored By Metabolon

Five Translational Insights Key to a Successful First-in-Human (FIH) Study – Metabolite-Based Biomarker Discovery and Validation

Translational success rates from pre-clinical animal studies to human clinical trials remain frustratingly low. Learn how metabolomics helps you bridge between the theoretical & practical, between the function & actual activity of your drug molecule to get you closer to the phenotype, sooner.